Abstract
Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components involved in neurodegeneration to protect neurons from death. Cell cycle is a highly regulated process that controls the balance between proliferation, differentiation and death of every cell in the body. Aberrant expression and function of components of the cell cycle machinery have been linked to neurodegenerative diseases, in which different types of neuronal cells become dysfunctional and die in response to toxic insults. Since neurons are postmitotic cells, re-entry into the cell cycle has been shown to be pathological and contributes to the process of neurodegeneration. Moreover, an increasing number of studies highlight the importance of the role of cell cycle components outside the cell cycle and their involvement in neurodegenerative disorders. Here, we discuss the pleiotropic effects of PACAP on cell cycle machinery and the implication for the treatment of neurodegenerative diseases.
Keywords: Neurodegeneration, cell cycle re-entry, pituitary adenylyl cyclase activating polypeptide (PACAP), apoptosis, therapy, adult neurons.
Current Pharmaceutical Design
Title:Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases
Volume: 24 Issue: 33
Author(s): María José Polanco*Maria Pennuto*
Affiliation:
- Laboratory of Pharmacology and Toxicology, Department of Pharmaceutical and Health Sciences, Faculty of Pharmacy, San Pablo CEU University, Madrid,Spain
- Department of Biomedical Sciences, University of Padova, 35100 Padova,Italy
Keywords: Neurodegeneration, cell cycle re-entry, pituitary adenylyl cyclase activating polypeptide (PACAP), apoptosis, therapy, adult neurons.
Abstract: Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components involved in neurodegeneration to protect neurons from death. Cell cycle is a highly regulated process that controls the balance between proliferation, differentiation and death of every cell in the body. Aberrant expression and function of components of the cell cycle machinery have been linked to neurodegenerative diseases, in which different types of neuronal cells become dysfunctional and die in response to toxic insults. Since neurons are postmitotic cells, re-entry into the cell cycle has been shown to be pathological and contributes to the process of neurodegeneration. Moreover, an increasing number of studies highlight the importance of the role of cell cycle components outside the cell cycle and their involvement in neurodegenerative disorders. Here, we discuss the pleiotropic effects of PACAP on cell cycle machinery and the implication for the treatment of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Polanco José María *, Pennuto Maria*, Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases, Current Pharmaceutical Design 2018; 24 (33) . https://dx.doi.org/10.2174/1381612825666181127102311
DOI https://dx.doi.org/10.2174/1381612825666181127102311 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review
Current Alzheimer Research Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Editorial: In Silico Methodologies Applied to Drug Discovery
Combinatorial Chemistry & High Throughput Screening Insilico Analysis of Post-Translational Modifications in DRD2 Receptor Protein in Schizophrenic Patients
Current Proteomics Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis
CNS & Neurological Disorders - Drug Targets Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Copy Number Variants in Neurological Disorder
Current Genomics Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Cholinesterase Inhibitory Activities of N-Phenylthiazol-2-Amine Derivatives and their Molecular Docking Studies
Medicinal Chemistry Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone
Current Medicinal Chemistry Acute Effects of Neutrophil-Derived Oxidative Stress on Pulmonary Microvasculature
Current Respiratory Medicine Reviews Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Anti-neoplastic and Calcium modulatory action of Caffeic acid phenethyl ester and Dasatinib in C6 glial cells: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Clinical Aspects of Melatonin Intervention in Alzheimers Disease Progression
Current Neuropharmacology Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design Myostatin in the Pathophysiology of Skeletal Muscle
Current Genomics